Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Circular RNA expression pattern in cisplatin-resistant osteosarcoma cells
Jianhua Han1, Zhiqiang Ye1, Qinglei Kong1
1Department of Emergency, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Background:
Cisplatin resistance associated with circular RNA (circRNA) in osteosarcoma (OS) is not fully understood. The present study aimed to reveal the expression profile of circRNAs related to cisplatin resistance in OS.
Methods:
Cisplatin-resistant OS cell lines (U2OS-R and MG63-R) were induced using different concentrations of cisplatin and RNA sequencing (RNA-seq) was performed to screen differentially expressed circRNAs in these cells. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict the function of the differentially expressed circRNAs. The circRNAs identified by RNA-seq were randomly selected for expression identification by quantitative real-time polymerase chain reaction (qRT-PCR).
Results:
A total of 343 circRNAs were differentially expressed in U2OS-R cells compared with U2OS cells. Among these circRNAs, 253 were upregulated and 90 were downregulated. Analysis of the characteristics of the differentially expressed circRNAs showed that upregulated circRNAs were mainly distributed in chromosomes 1, 2, 3, 7, and 8, while downregulated circRNAs were distributed in all chromosomes except the X chromosome. GO and KEGG analyses revealed that the differentially expressed circRNAs were enriched in metabolic pathways, pathways in cancer, adherens junction, proteoglycans in cancer, and transcriptional misregulation in cancer pathway. Furthermore, three circRNAs (hsa_circ_0008336, hsa_circ_0004664, and hsa_circ_0003302) were upregulated in both U2OS-R and MG63-R cells.
Conclusions:
Cisplatin-resistant cell lines showed a distinct circRNA expression profile. In particular, hsa_circ_0008336, hsa_circ_0004664, and hsa_circ_0003302 were upregulated in cisplatin-resistant cells and may be involved in the pathology of cisplatin resistance in OS.
Insights
Circular RNAs (circRNAs) show distinct expression profiles in cisplatin-resistant osteosarcoma (OS) cells. Three specific circRNAs (hsa_circ_0008336, hsa_circ_0004664, hsa_circ_0003302) were upregulated, suggesting their potential role in OS cisplatin resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cisplatin resistance is a significant challenge in osteosarcoma (OS) treatment.
- The role of circular RNAs (circRNAs) in OS cisplatin resistance remains largely unexplored.
Purpose of the Study:
- To investigate the expression profile of circRNAs associated with cisplatin resistance in OS.
- To identify specific circRNAs that may contribute to cisplatin resistance in OS.
Main Methods:
- Induction of cisplatin-resistant OS cell lines (U2OS-R and MG63-R).
- RNA sequencing (RNA-seq) to identify differentially expressed circRNAs.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
- Quantitative real-time polymerase chain reaction (qRT-PCR) for validation.
Main Results:
- A total of 343 circRNAs were differentially expressed in cisplatin-resistant OS cells.
- 253 circRNAs were upregulated and 90 were downregulated.
- Three circRNAs (hsa_circ_0008336, hsa_circ_0004664, and hsa_circ_0003302) were consistently upregulated in both resistant cell lines.
- Enrichment analysis indicated involvement in cancer pathways and metabolic processes.
Conclusions:
- Cisplatin-resistant OS cells exhibit a unique circRNA expression signature.
- Upregulated circRNAs, specifically hsa_circ_0008336, hsa_circ_0004664, and hsa_circ_0003302, are potential biomarkers and therapeutic targets for overcoming cisplatin resistance in OS.
